British Biotech startup shows 50% improvement in Atopic Dermatitis

14/06/2016 - 2 minutes

Ziarco has received positive results from a Phase II trial with its leading candidate, which has shown to improve symptoms of atopic dermatitis by 50%, giving it the potential to fill the current need for a safe oral treatment for this inflammatory skin disease.

ziarco_phase2_atopic_dermatitis_zplZiarco is a private biotech with a clinical-stage pipeline for inflammatory skin diseases such as atopic dermatitis (also known as eczema) and psoriaris.

Founded in 2012, Ziarco has grown fast and even raised €27M back in 2014. It is located in the Discovery Park in Sandwich (yes, that’s really a city in the UK), having Centauri (which was involved in a creation of a spin-off earlier this year) and Pfizer as neighbors.

Ziarco has now received positive Phase II results for its leading candidate, ZPL-389. The study enrolled 98 people with moderate to severe atopic dermatitis, a chronic skin condition characterized by rashes and swelling.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member